These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 30919094)
21. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial). Ebbers SC; Braat AJAT; Moelker A; Stokkel MPM; Lam MGEH; Barentsz MW Trials; 2020 Feb; 21(1):141. PubMed ID: 32024533 [TBL] [Abstract][Full Text] [Related]
22. Resolution of Malignant Ascites and Stabilization of Metastases in a Patient With Small Bowel Neuroendocrine Tumor With 177Lu-DOTATATE Following Progression After 17 131I-MIBG Treatments and Chemotherapy. Makis W; McCann K; Buteau FA; McEwan AJ Clin Nucl Med; 2015 Jul; 40(7):564-6. PubMed ID: 25546192 [TBL] [Abstract][Full Text] [Related]
23. Combined Adnan A; Basu S J Nucl Med Technol; 2020 Sep; 48(3):292-294. PubMed ID: 32358042 [TBL] [Abstract][Full Text] [Related]
24. Orbital Metastases of Neuroendocrine Tumors Treated With 177Lu-DOTATATE PRRT or 131I-MIBG Therapies. Makis W; McCann K; McEwan AJ Clin Nucl Med; 2016 Feb; 41(2):137-41. PubMed ID: 26447382 [TBL] [Abstract][Full Text] [Related]
25. Safety and outcomes of Lin E; Chen T; Little A; Holliday L; Roach P; Butler P; Hosking E; Bailey E; Elison B; Currow D Intern Med J; 2019 Oct; 49(10):1268-1277. PubMed ID: 31062490 [TBL] [Abstract][Full Text] [Related]
27. Large cell neuroendocrine carcinoma of the lung with atypical evolution and a remarkable response to lutetium Lu 177 dotatate. Escala Cornejo RA; García-Talavera P; Navarro Martin M; Pérez López B; García Muñoz M; Tamayo Alonso MP; Cruz Hernández JJ Ann Nucl Med; 2018 Oct; 32(8):568-572. PubMed ID: 30051167 [TBL] [Abstract][Full Text] [Related]
28. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC. Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388 [TBL] [Abstract][Full Text] [Related]
29. Hervás I; Bello P; Falgas M; Del Olmo MI; Torres I; Olivas C; Vera V; Oliván P; Yepes AM Rev Esp Med Nucl Imagen Mol; 2017; 36(2):91-98. PubMed ID: 27889527 [TBL] [Abstract][Full Text] [Related]
30. Resolution of Hyperreninemia, Secondary Hyperaldosteronism, and Hypokalemia With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy in a Patient With Pancreatic Neuroendocrine Tumor. Makis W; McCann K; Riauka TA; McEwan AJ Clin Nucl Med; 2015 Nov; 40(11):880-4. PubMed ID: 26359564 [TBL] [Abstract][Full Text] [Related]
31. Availability of both [ Basu S; Parghane RV; Banerjee S Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):756-758. PubMed ID: 31628515 [No Abstract] [Full Text] [Related]
32. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066 [TBL] [Abstract][Full Text] [Related]
33. High clinical and morphologic response using Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267 [TBL] [Abstract][Full Text] [Related]
34. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update. Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750 [TBL] [Abstract][Full Text] [Related]
35. Neuroendocrine Tumor Therapy: Mittra ES AJR Am J Roentgenol; 2018 Aug; 211(2):278-285. PubMed ID: 29949416 [TBL] [Abstract][Full Text] [Related]
36. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Forrer F; Uusijärvi H; Waldherr C; Cremonesi M; Bernhardt P; Mueller-Brand J; Maecke HR Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1257-62. PubMed ID: 15197500 [TBL] [Abstract][Full Text] [Related]
37. Successful Repeated Peptide Receptor Radionuclide Therapies in Renal Neuroendocrine Tumor With Osseous Metastasis. Yordanova A; Mayer K; Essler M; Ahmadzadehfar H Clin Nucl Med; 2016 Dec; 41(12):977-979. PubMed ID: 27749410 [TBL] [Abstract][Full Text] [Related]
38. Guidance on Abbott A; Sakellis CG; Andersen E; Kuzuhara Y; Gilbert L; Boyle K; Kulke MH; Chan JA; Jacene HA; Van den Abbeele AD J Nucl Med Technol; 2018 Sep; 46(3):237-244. PubMed ID: 30076245 [No Abstract] [Full Text] [Related]
39. Comparison of renal uptake of 68Ga-DOTANOC PET/CT and estimated glomerular filtration rate before and after peptide receptor radionuclide therapy in patients with metastatic neuroendocrine tumours. Kaewput C; Vinjamuri S Nucl Med Commun; 2016 Dec; 37(12):1325-1332. PubMed ID: 27612032 [TBL] [Abstract][Full Text] [Related]
40. Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy. Makis W; McCann K; Riauka TA; McEwan AJ Clin Nucl Med; 2016 Jan; 41(1):50-2. PubMed ID: 26359569 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]